Systems biology and combination therapy in the quest for clinical efficacy
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Combinatorial control of biological processes, in which redundancy and multifunctionality are the norm, fundamentally limits the therapeutic index that can be achieved by even the most potent and highly selective drugs. Thus, it will almost certainly be necessary to use new 'targeted' pharmaceuticals in combinations. Multicomponent drugs are standard in cytotoxic chemotherapy, but their development has required arduous empirical testing. However, experimentally validated numerical models should greatly aid in the formulation of new combination therapies, particularly those tailored to the needs of specific patients. This perspective focuses on opportunities and challenges inherent in the application of mathematical modeling and systems approaches to pharmacology, specifically with respect to the idea of achieving combinatorial selectivity through use of multicomponent drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, these examples demonstrate the potential use of mechanistic and data driven modelling in dose selection, studies of drug-drug interaction, and identification of the most efficient therapies [338].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [338]
In the citing paper
“Accurate predictions of combination treatments from single treatment data would allow a cost-effective pre-selection of promising drug candidates for experimental follow-up, which is highly relevant for modern personalized medicine (Fitzgerald et al., 2006).”
From Efficient Parameter Estimation Enables the Prediction of Drug Response Using a Mechanistic Pan-Cancer Pathway Model (2018) · cites this paper as Fitzgerald et al., 2006
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Arzneimittelforschung: Eine Zukunftsoption für Ärzte?
Bethke, T. D. (2012) · Der Pneumologe · doi:10.1007/s10405-012-0601-3 · Cited by 3,261
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“However, growth of cells in the presence of IGF-1 was found to be unaffected when mTOR was inhibited with a rapamycin analog; instead, activity of the upstream regulator Akt increase”
BackgroundRobustness in the Strategy of Scientific Model Building
Box, G. E. P. (1979) · Robustness in Statistics · doi:10.1016/b978-0-12-438150-6.50018-2 · Cited by 1,562
Enzyme and metabolic inhibitors
Webb, J. L. (1963) · Academic Press eBooks · doi:10.5962/bhl.title.7320 · Cited by 1,514
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434
Berenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Cell-signalling dynamics in time and space
Kholodenko, B. N. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1838 · Cited by 1,347 · cited 1×
“However, large models with multiple signaling circuits raise new conceptual issues, such as how best to represent the partitioning of shared components (for example, Ras, MAP kinases and others) among potentially competing pathway”
BackgroundThe tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314 · cited 1×
“Inhibition of mTOR is promising as an anticancer strategy, as many proteins lying upstream and downstream of mTOR are deregulated in a human cance”
Background
Cited by
Items 401–500 of 570
Glinkina, K., Némati, F., Teunisse, A. F. A. S., Gelmi, M. C., Etienne, V., Kuipers, M. J., Alsafadi, S., Jager, M. J., Decaudin, D., & Jochemsen, A. G. (2022) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.63.13.14 · Cited by 7
Bifurcation-based approach reveals synergism and optimal combinatorial perturbation
Liu, Y., Li, S., Liu, Z., & Wang, R. (2016) · Journal of Biological Physics · doi:10.1007/s10867-016-9414-7 · Cited by 6
“Synergism has been quantified by using the Chou-Talalay method [21–23], Loewe combination index [24, 25], Bliss independence [26, 27], and the degrees of non-linear blending and additive synergism [28].”
MethodContext‐dependent regulation of receptor tyrosine kinases: Insights from systems biology approaches
Lam, I., Pickering, C. M., & Gabhann, F. M. (2018) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1437 · Cited by 8
“Computational analysis of the signaling networks using experimentally-validated mechanistic models can provide insights into the critical nodes in the signaling network (Chen et al., 2009; Fitzgerald et al., 2006; Schoeberl, Nielsen, & Paxson, 2006).”
MethodCombinatorial approaches for treating neuropsychiatric social impairment
Don, W., Tsheringla, S., McPartland, J. C., & Allsop, S. A. (2022) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2021.0051 · Cited by 6
“This highlights that multifunctionality and redundancy are continuing challenges of creating targeted therapies for social cognition [148].”
Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma
Glinkina, K., Teunisse, A. F. A. S., Gelmi, M. C., de Vries, J., Jager, M. J., & Jochemsen, A. G. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000911 · Cited by 7
Mesoporous Silica Nanoparticles for Cancer Therapy
Liu, Q., & Xia, W. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-456-2_13 · Cited by 6
Fang, H.-B., Huang, H., Clarke, R., & Tan, M. (2016) · Journal of Computational Systems Biology · doi:10.15744/2455-7625.2.101 · Cited by 6
Does complementary and alternative medicine represent only placebo therapies?
Bland, J. K. S. (2008) · PubMed · Cited by 6
Kirouac, D., Lahdenranta, J., Du, J., Yarar, D., Onsum, M., Nielsen, U., & McDonagh, C. (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.19 · Cited by 5
“The use of individually tailored drug combinations has been widely touted as a solution to improve the effectiveness of anticancer drug therapy.(43) However, the design of such biomarker-based regimens through empirical screening alone is largely unfeasible.”
BackgroundSelf-citationSystems Pharmacology: Enabling Multidimensional Therapeutics
Maudsley, S. R., Leysen, H., van Gastel, J., & Martin, B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00017-7 · Cited by 6
Huang, X., & Chen, D. Y. ‐. (2012) · ChemMedChem · doi:10.1002/cmdc.201200287 · Cited by 5
Khan, I., Yusuf, M. A., Ansari, I. A., & Akhtar, M. S. (2018) · Springer eBooks · doi:10.1007/978-981-10-8417-1_6 · Cited by 5
Dynamical Synergy of Drug Combinations during Cancer Chemotherapy
Castorina, P., Martorana, E., & Forte, S. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111873 · Cited by 5
Pooled Screening for Synergistic Interactions Subject to Blocking and Noise
Li, K., Precup, D., & Perkins, T. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085864 · Cited by 6
“Multi-component therapies, which rely upon synergistic interactions between individually ineffective or weak drugs, are increasingly being used to address complex diseases such as cancer, HIV/AIDS, diabetes, and immune disorders [8–11].”
BackgroundRoles of Raft-Anchored Adaptor Cbp/PAG1 in Spatial Regulation of c-Src Kinase
Saitou, T., Kajiwara, K., Oneyama, C., Suzuki, T., & Okada, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093470 · Cited by 5
In Vitro Three-Dimensional Cell Cultures as Tool for Precision Medicine
Silvestri, A., Schumacher, D., Silvestrov, M., Schäfer, R., Reinhard, C., Hoffmann, J., Boehnke, K., & Regenbrecht, C. R. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-53661-3_14 · Cited by 5
Compromise design for combination experiment of two drugs
Huang, H., & Chen, X. (2020) · Computational Statistics & Data Analysis · doi:10.1016/j.csda.2020.107150 · Cited by 5
Manmuan, S., Manmuan, P., YOYKAEW, P., THUETONG, P., ASIPONG, P., RIANTONG, N., & Tantisira, M. H. (2021) · Walailak Journal of Science and Technology (WJST) · doi:10.48048/wjst.2021.9016 · Cited by 6
“The discovery of natural herbal chemopreventive medicine in combination treatment will not only enhance the effectiveness of the chemotherapy but can also reduce the side effects of chemotherapeutic drugs [9].”
BackgroundPredicting combinations of drugs by exploiting graph embedding of heterogeneous networks
Song, F., Tan, S., Dou, Z., Liu, X., & Ma, X. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-04567-4 · Cited by 5
“Specifically, the Loewe additivity model assumes that drugs can be combines if the inhibitors have the same or similar mechanism of regulations, whereas Bliss makes use of independence assumption based on probability theory [18].”
MethodA machine learning framework for predicting synergistic and antagonistic drug combinatorial efficacy
Mei, S. (2022) · Journal of Mathematical Chemistry · doi:10.1007/s10910-022-01331-0 · Cited by 5
“Loewe and Bliss models [16], Chou-Talalay method [17], chemogenomic profile [18]) are developed to quantitively measure the synergy that the overall effect of drug combinations is greater than the sum of effects of individual drugs.”
MethodWhen Medicine Meets Engineering—Paradigm Shifts in Diagnostics and Therapeutics
Wang, H., Silva, A., & Ho, C. (2013) · Diagnostics · doi:10.3390/diagnostics3010126 · Cited by 6
“Combination of multiple drugs has many advantages over single drug therapy: (1) drug combinations enhance the potency of the therapy by taking advantage of the drug synergistic or additive effects; (2) the synergies among many drugs may reduce the dosage levels, which usually imply low toxicities and side effects; (3)…”
BackgroundMining linguistic cues for query expansion
Guo, S. H., & Ramakrishnan, N. (2009) · ACM International Conference on Information and Knowledge Management (CIKM) · doi:10.1145/1645953.1645998 · Cited by 5
“For instance, in treating complex diseases such as cancers [35], multiple, or multi-component, drugs are usually administered in order to enhance combinatorial selectivity [12].”
BackgroundSystem biology approaches for drug repurposing
Israr, J., Alam, S., & Kumar, A. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.03.027 · Cited by 7
Optimizing drug synergy prediction through categorical embeddings in deep neural networks
Lastre, M. G., Salas, P. G. D. P., & Guantes, R. (2025) · Biology Methods and Protocols · doi:10.1093/biomethods/bpaf033 · Cited by 4
“Drug combinations conferring synergy (usually quantified with respect to a null model where combined drug effects are additive or independent [5, 6]) are promising candidates for effective therapies.”
Ahmad, S., Qazi, S., Bano, N., Uddin, R., Gautam, P. K., & Raza, K. (2026) · PLoS ONE · doi:10.1371/journal.pone.0344028 · Cited by 4
“This polypharmacological approach could complement the growing interest in precision medicine and its recognition that cancer is a multi-pathway disease requiring treatment from multiple pathways [79,80].”
A comparative study of in vitro dose–response estimation under extreme observations
Fang, X., & Zhou, S. (2023) · Biometrical Journal · doi:10.1002/bimj.202200092 · Cited by 4
“For example, the interaction index (Greco et al., 1995), a popular metric of drug synergy based on Loewe additivity (Fitzgerald et al., 2006; Greco et al., 1995), can be written as a function of 𝛽 s.”
BackgroundRevolutionizing fixed-dose combinations with long-acting microsphere
Hu, Z., Xiao, X., Zhang, G., & Li, Y. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107032 · Cited by 5
Dilazep synergistically reactivates latent HIV-1 in latently infected cells
Zeng, H., Liu, S., Wang, P., Qu, X., Ji, H., Wang, X., Zhu, X., Song, Z., Yang, X., Ma, Z., et al. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3662-z · Cited by 4
“lower concentrations could be effective, this could help eliminate toxicity [42, 43].”
BackgroundKeny, E. S., & Kale, P. P. (2022) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2021-0264 · Cited by 4
Yang, H., Goudar, V. S., Hung, Y., Ouyang, C., Rashid, M. B. M. A., Juo, L.-Y., Wu, J., Cheng, Y., Wei, P., Tzeng, H.-E., et al. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202200298 · Cited by 4
Tripathi, S., Rana, R., Chakradhar, J. V. U. S., Mishra, K., Jaiswal, S., Sethi, M., Tiwari, A. K., & Chourasia, M. K. (2025) · Bioanalysis · doi:10.1080/17576180.2025.2518044 · Cited by 4
Rad, A. N., Shams, G., Avelar, R. A., Morowvat, M. H., & Ghasemi, Y. (2022) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2022.100920 · Cited by 4
Modern cancer drug discovery: integrating targets, technologies and treatments
Workman, P., & Collins, I. (2008) · Elsevier eBooks · doi:10.1016/b978-012369448-5.50004-5 · Cited by 8
Challenges in Combinational Oncology Studies
Macpherson, I. R., & Cassidy, J. (2008) · Pharmaceutical Medicine · doi:10.1007/bf03256688 · Cited by 4
Cellular features predicting susceptibility to ferroptosis: insights from cancer cell-line profiling
Viswanathan, V. S. (2015) · doi:10.7916/d8h9940v · Cited by 4
Rational Drug Design of Small Molecule Anticancer Agents: Preclinical Discovery
Collins, I., Molife, R., Kaye, S. B., & Workman, P. (2007) · Wiley eBooks · doi:10.1002/9780470025079.chap96.pub2 · Cited by 5
Wu, J., & Guo, D. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118842 · Cited by 4
Singh, G., Gupta, S., & Gupta, P. (2025) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.19.3.42 · Cited by 3
Experimentally calibrated multiscale model predicts schedule dependent drug combination effects
Hayoun-Mya, O., Montagud, A., Valencia, A., & Ponce-de-León, M. (2026) · npj Systems Biology and Applications · doi:10.1038/s41540-026-00669-4 · Cited by 4
Modeling the mitotic regulatory network identifies highly efficient anti-cancer drug combinations
Wu, Y., Zhuo, X., Dai, Z., Guo, X., Wang, Y., Zhang, C., & Lai, L. (2014) · Molecular BioSystems · doi:10.1039/c4mb00610k · Cited by 4
Structural analysis of Petri nets for modeling and analyzing signaling pathways
Behinaein, B., Rudie, K., & Sangrar, W. (2014) · Conference proceedings - Canadian Conference on Electrical and Computer Engineering · doi:10.1109/ccece.2014.6901004 · Cited by 3
“Indeed ODEs models have been proposed to be essential for identifying combination therapies since they can account for feedback by simulating the behavior of the system [3].”
BackgroundColavito, S. A., Platt, J. T., Held, M. A., Liu, Z. Z., Sokup, R., & Stern, D. F. (2019) · Oncotarget · doi:10.18632/oncotarget.27104 · Cited by 3
“Super- and sub-additivity is plotted using the Bliss independence model [11].”
BackgroundMethodInfluentialA mechanistic assessment of the nature of pharmacodynamic drug-drug interaction in vivo and in vitro
Bisaso, K. R., Mukonzo, J., & Ette, E. (2023) · In Silico Pharmacology · doi:10.1007/s40203-023-00168-y · Cited by 3
“This is because most diseases are pathophysiologically controlled in a combinatorial manner at the subcellular level by target proteins that are involved in a multiplicity of cellular processes (Fitzgerald et al. 2006).”
BackgroundDesigning optimal combination therapy for personalised glioma treatment
Noman, N., & Moscato, P. (2020) · Memetic Computing · doi:10.1007/s12293-020-00312-7 · Cited by 3
Computational analysis of synergism in small networks with different logic
Chen, M., & Wang, R. (2022) · Journal of Biological Physics · doi:10.1007/s10867-022-09620-0 · Cited by 3
“To quantify synergism of combinatorial perturbations, different approaches have been introduced, e.g., the Chou-Talalay method [24–26] and the Loewe combinatorial indicator (CI) [27].”
MethodInfluentialShi, M., Hou, J., Shao, S., Liang, W., Wang, S., Yang, Y., Guo, Z., & Pan, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032498 · Cited by 3
“Traditional treatments include surgery, chemotherapy, and radiotherapy, each of which has its limitations in clinical practice and needs to be complemented by other therapeutic methods in combination with synergistic treatment [46,47].”
BackgroundFuture Outlook for Systems Biology
Young, D. L., & Michelson, S. (2011) · Wiley eBooks · doi:10.1002/9781118016435.ch14 · Cited by 3
Tan, M. T., Fang, H., Huang, H., & Yang, Y. (2016) · ICSA book series in statistics · doi:10.1007/978-3-319-42568-9_18 · Cited by 4
Adeoye-Isijola, M. O., Osopale, B. A., & Olajuyigbe, O. O. (2019) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2019.6.3.0006 · Cited by 3
“By aiming at different target sites, simultaneously, in a bacterial pathogen, it is possible to obtain a more-than-additive response compared to the activity of the individual agents alone [46, 47].”
BackgroundVakil, V., & Trappe, W. K. (2020) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2020.3045315 · Cited by 3
Jeong, J.-H., Ojha, U., Jang, H., Kang, S., Lee, S.-H., & Lee, Y. M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00737-x · Cited by 3
Modeling and Simulation in Clinical Drug Development
Nedelman, J. R., Bretz, F., Fisch, R. D., Георгиева, A., Hsu, C., Kahn, J. M., Kawai, R., Lowe, P. J., Maca, J., Pinheiro, J. C., et al. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse242 · Cited by 3
Regulated cell death plasticity in cancer: thresholds, reversibility, and therapeutic failure
Jawwad, T., Baba, S. K., Surendranath, A., Chaudhary, E., Jeelani, G., Akil, A. S. A.-S., Menhali, A. A., Bhat, A. A., & Mirza, S. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08584-2 · Cited by 2
“Therapies may need to target both the mechanisms that drive execution and the systems that buffer against it [391, 392].”
In-silco investigation of EGFR network in kidney cancer: a drug discovery approach
Ahmad, S. U. (2020) · Pure and Applied Biology · doi:10.19045/bspab.2020.90166 · Cited by 2
Graham, E., Harbron, C. G., & Jaki, T. (2023) · Statistical Methods in Medical Research · doi:10.1177/09622802231151218 · Cited by 2
“Alongside reducing side effects, combination therapies are often able to minimise drug resistance whilst still achieving efficacy.(1) This is often realised by combining treatments that are similar in terms of the size of their therapeutic effect, but different in terms of their mode of action or toxicity.”
Fusing Micro- and Macro-Scale Information to Predict Anticancer Synergistic Drug Combinations
Wang, X., Zhu, H., Liu, Q., & Liu, Q. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3500789 · Cited by 2
Inference of marker genes of subtle cell state changes via iLR: iterative logistic regression
Liu, Y., Baugh, A. G., Torres, E. T. R., & MacLean, A. L. (2026) · Bioinformatics · doi:10.1093/bioinformatics/btag051 · Cited by 4
“Furthermore, combination therapies—designed to enhance efficacy and prevent drug resistance—are increasingly common in clinical practice (Fitzgerald et al. 2006).”
Identification of combination therapy models using a neuro fuzzy identification scheme
Giotis, T., Christodoulou, M. A., & Boutalis, Y. (2011) · Mediterranean Conference on Control and Automation (MED) · doi:10.1109/med.2011.5983229 · Cited by 2
Systems Biology in Drug Discovery
Tucker‐Kellogg, G., Aggarwal, A., Blanchard, K. L., & Gaynor, R. B. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-372550-9.00017-1 · Cited by 2
Lescarbeau, R. M., & Kaplan, D. L. (2013) · Molecular BioSystems · doi:10.1039/c3mb70403c · Cited by 2
Chua, H. E., Bhowmick, S. S., Tucker‐Kellogg, L., & Dewey, C. F. (2012) · ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics (ACM-BCB) · doi:10.1145/2382936.2382937 · Cited by 3
“Combinatorial control involving redundancy and multifunctionality of biological signaling processes are often implicated in diseases [12] such as cancer.”
BackgroundMethodPopov, S. G. (2011) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v2.i5.98 · Cited by 2
ИНЖЕНЕРИЯ ТЕРАПЕВТИЧЕСКИХ АНТИТЕЛ: ТЕОРИЯ И ПРАКТИКА#, "Молекулярная биология"
Луговской, А. А. (2017) · Molecular Biology · doi:10.7868/s0026898417060027 · Cited by 2
Drug Combination Studies, Uniform Experimental Design and Extensions
Tan, M. T., & Fang, H. (2020) · Springer eBooks · doi:10.1007/978-3-030-46161-4_8 · Cited by 2
Machine Learning Perspective in Cancer Research
Sharma, A., & Rani, R. (2020) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-2742-9.ch008 · Cited by 2
Phytopharmaceuticals in Cancer Treatment
Fakhri, K. U., Alotaibi, B. S., Kumar, S., Kumar, U., Sonkar, S. C., Mathur, A., Kazim, Z., Perwez, A., Yasin, D., Zeya, B., et al. (2020) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-6530-8.ch025 · Cited by 2
Magic bullets: Drug repositioning and drug combinations
Yella, J., & Jegga, A. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00116-x · Cited by 2
Luo, J., Piao, C., Jin, D., Wang, L., Zhao, X., Lian, F., & Tong, X. (2022) · ChemistrySelect · doi:10.1002/slct.202103534 · Cited by 2
Engineering Antibodies as Drugs: Principles and Practice
Lugovskoy, A. A. (2017) · Molecular Biology · doi:10.1134/s0026893317060097 · Cited by 3
Fröhlich, F. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-3008-2_3 · Cited by 2
Trecento : in silico network-driven identification of target combinations for combination therapy
Chua, H. E. (2015) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/64995 · Cited by 2
Mining Truth Tables and Straddling Biclusters in Binary Datasets
Owens, C. C. (2009) · VTechWorks (Virginia Tech) · Cited by 2
Six wedges to curing diseasePreprint
Hochberg, M. (2017) · doi:10.7287/peerj.preprints.3378v1 · Cited by 2
Identifying biomarkers of anti-cancer drug synergy using multi-task learningPreprint
Aben, N., de Ruiter, J. R., Bosdriesz, E., Kim, Y., Bounova, G., Vis, D. J., Wessels, L. F. A., & Michaut, M. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/243568 · Cited by 2
“As the response variable for our model, we used the synergy scores as provided in the DREAM data, which were based on a Loewe additivity model [5,8].”
MethodPeptidoglycan precursor synthesis along the sidewall of pole-growing mycobacteriaPreprint
García‐Heredia, A., Pohane, A. A., Melzer, E. S., Carr, C. R., Fiolek, T. J., Rundell, S. R., Lim, H. C., Wagner, J. C., Morita, Y. S., Swarts, B. M., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/292607 · Cited by 2
Zhao, L., & Luo, J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.05.627115 · Cited by 2
Modeling combination therapies in patient cohorts and cell cultures using correlated drug action
Arun, A. S., Kim, S., Ahsen, M. E., & Stolovitzky, G. A. (2024) · iScience · doi:10.1016/j.isci.2024.108905 · Cited by 1
Liu, J., Zheng, S.-L., Wu, J., Zheng, M., Cai, D.-T., Zhang, Y., Sun, J. G., Liu, Y.-H., Liao, X., & Yu, Y. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1502558 · Cited by 1
Xu, H., Wu, Z., Wang, P., Gong, J., Qiu, L., Gu, Y., Zhan, L., Tian, F., & Gao, Z. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04396-w · Cited by 1
“Combination therapy for epilepsy is a viable strategy that can significantly reduce the risk of developing drug resistance and minimize side effects [ 16 ].”
Chen, Z., Hong, Y., Xu, Y., Zhang, X., Zhang, M., Hu, R., Liu, J., & Liu, X. (2025) · International Joint Conference on Neural Networks (IJCNN) · doi:10.1109/ijcnn64981.2025.11229051 · Cited by 1
“In recent years, combination therapies involving multiple drugs have been considered a powerful strategy to enhance treatment efficacy, mitigate host toxicity, and overcome drug resistance [4], widely applied in treating various complex diseases [5].”
Tseng, P., Sinenko, I. L., Chambon, M., Banfi, D., Zugbi, S., Cancela, M. B., Glinkina, K. A., Turcatti, G., Stathopoulos, C., Schaiquevich, P. S., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0339334 · Cited by 1
“The effect of carboplatin and gemcitabine, alone and in combination, on cell viability was evaluated, and potential synergistic interactions were assessed using the Excess over Bliss (EOB) algorithm [27,28].”
Cho, M. S., Lee, Y., Kim, K. D., Choi, M., Park, S. Q., Lee, S.-H., Nam, H.-S., & Lee, Y. (2026) · Life · doi:10.3390/life16040615 · Cited by 1
Hussein, H. A., Borrel, A., Regad, L., Flatters, D., Badel, A., Geneix, C., Petitjean, M., Camproux, A., & Taboureau, O. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00017-1 · Cited by 2
Computational Tools for Systems Biology
Klipp, E., & Krause, F. (2011) · Springer eBooks · doi:10.1007/978-94-007-1567-7_8 · Cited by 1
“en sufficiently well described networks and properties of the interaction of compound, mathematical models can be useful for predicting targets for treatment and testing the outcome of different target positions, treatment strengths, target combinations or temporal combination scenarios (Fitzgerald et al. 2006; Schulz…”
BackgroundA Network Target-based Approach for Evaluating Multicomponent Synergy
Li, S., Ningbo, Z., & Zhang, B. (2010) · Cited by 1
Integrative Systems Biology I—Biochemistry: Phase I Lead Discovery and Molecular Interactions
Prokop, A., & Michelson, S. (2012) · SpringerBriefs in pharmaceutical science & drug development · doi:10.1007/978-94-007-2849-3_3 · Cited by 1
DISCOVERY OF MOLECULARLY TARGETED THERAPIES
Regan, K., Abrams, Z. B., Sharpnack, M. F., Srivastava, A., Huang, K., Shah, N. H., & Payne, P. (2015) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789814749411_0001 · Cited by 1
“However, systematic approaches to the use of that knowledge in order to directly inform the selection of targeted molecular therapies for “real world” patients are extremely limited [1, 3, 6-9].”
BackgroundPredicting Toxicity for Simple Water-Based Drilling Fluids Using a Response Surface Methodology
Cortner, T., & Trickey, E. (2016) · SPE International Conference on Health, Safety and Environment in Oil and Gas Exploration and Production · doi:10.2118/179212-ms · Cited by 1
Using Systems Pharmacology to Advance Oncology Drug Development
Kirouac, D. C. (2016) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-44534-2_19 · Cited by 2
Ağca, C. A., Kırıcı, M., Abdurrahman, C. A. N., & Yumak, Y. (2019) · Kırıkkale Üniversitesi Tıp Fakültesi Dergisi · doi:10.24938/kutfd.465470 · Cited by 4
Multi-parametric characterization of drug effects on cells
Paran, Y., Liron, Y., Batsir, S., Mabjeesh, N. J., Geiger, B., & Kam, Z. (2020) · F1000Research · doi:10.12688/f1000research.26254.2 · Cited by 1
Bioinformatic strategies to understand the complexities of medicinal natural product mixtures
Caesar, L. K. (2019) · NC Digital Online Collection of Knowledge and Scholarship (The University of North Carolina at Greensboro) · Cited by 1
A Network-Based Approach for Identifying Effective Drug Combination
Wu, Z., & Chen, L. (2009) · Cited by 1
Screening combinatorial perturbations via a bifurcation-based method
Liu, L., Chen, Q., & Wang, R. (2022) · Modern Physics Letters B · doi:10.1142/s0217984922500178 · Cited by 1
Lozano-Huntelman, N. A., Cook, E., Bullivant, A., Ida, N., Zhou, A., Boyd, S. M., & Yeh, P. J. (2025) · Evolution · doi:10.1093/evolut/qpaf023 · Cited by 1
“One solution to address the problem of antibiotic resistance is to use anti-biotics in combination (Brown & Wright, 2016; Brown et al., 2013; Fitzgerald et al., 2006; Foucquier & Guedj, 2015).”
The Application of Drug-Disease Models in the Development of Anti-Hyperglycemic Agents
Chien, J. Y., & Sinha, V. P. (2010) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4419-7415-0_9 · Cited by 1
“This bottom–up modeling (Fitzgerald et al. 2006) in the translational attempts to simulate the disease features and interaction of various pathways using algebraic and differential equations are being used to prioritize hypothesis, evaluate combination therapies and differentiate drug classes based on outcomes (Waters…”
MethodLiu, C. (2014) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Clinical Applications of Systems Biology Approaches
Iadevaia, S., Tabchy, A. B., Ram, P. T., & Mills, G. B. (2011) · Springer eBooks · doi:10.1007/978-94-007-1567-7_16 · Cited by 1
Bet Hedging in Pdr5-mediated Drug Resistance and a Mechanism for its Regulation
Azizi, A. (2014) · uO Research (University of Ottawa) · doi:10.20381/ruor-6494 · Cited by 2
“In addition, many pathogens need to be treated with drug cocktails to ensure their complete removal [96].”
BackgroundUsing Dependency Parses to Augment Feature Construction for Text Mining
Guo, S. H. (2012) · VTechWorks (Virginia Tech) · Cited by 1
Metadata
- Authors
- Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B., & Sorger, P. K.
- Affiliations
- Merrimack Pharmaceuticals (United States) (US)
- Harvard University (US)
- Corresponding author
- Sorger, Peter K
- Venue
- Nature Chemical Biology
- Published
- 2006-08-18
- Volume
- 2
- Issue
- 9
- Pages
- 458-466
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W1994663540
- Cited by
- 570
- References
- 68
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 23 · 2023: 28 · 2022: 30 · 2021: 23 · 2020: 32 · 2019: 36 · 2018: 39 · 2017: 40 · 2016: 45 · 2015: 41 · 2014: 45 · 2013: 34 · 2012: 36
- FWCI
- 12.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p50gm068762-10)
- National Institute of General Medical Sciences (GM 68762)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- combination therapy, systems biology, targeted therapy, therapeutic index, personalized medicine, cytotoxic chemotherapy
- MeSH terms
- Drug Therapy, Combination, Models, Biological, Feedback, Physiological, Systems Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.